Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Helicobacter Pylori GastritisHelicobacter Eradication
Interventions
DRUG

Modified bismuth-containing eradication treatment

"After the confirmation of Helicobacter pylori infection, eligible patients whether first line or rescue therapy will be assigned to receive:~\- A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all medications taken for 14 days.~Esomeprazole will be given at least 30 minutes before meals every 12 hours. Antibiotics will be given after meals every 8 hours and bismuth subcitrate at least 2 hours far from meals every 12 hours."

Sponsors
All Listed Sponsors
lead

Athens Medical Center

OTHER

NCT07146594 - Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia | Biotech Hunter | Biotech Hunter